Nate Grawey
About Nate Grawey
Nate (Nathaniel) Grawey is Tenon Medical’s Chief Commercial Officer, hired in connection with the SImmetry acquisition in August 2025; his employment is at‑will and governed by a specific employment agreement . The filings reviewed do not disclose his age or education; he was not listed among named executive officers or directors in the June 2025 proxy and his Q2 2025 employment disclosure does not include biographical details . He participated as a purchaser in Tenon’s November 2025 PIPE financing alongside other senior executives, indicating insider capital alignment .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| SImmetry (SI) | Former executive (title not disclosed) | Not disclosed | Hired by Tenon as CCO in connection with SI acquisition integration |
External Roles
- No external public-company directorships or outside roles are disclosed for Grawey in the filings reviewed .
Fixed Compensation
| Component | Value | Notes |
|---|---|---|
| Base Salary | $290,000 | At‑will employment |
| Benefits | Standard senior executive benefits (not itemized) | As per employment agreement |
Performance Compensation
| Incentive Type | Metric | Weighting | Target | Actual | Payout | Vesting |
|---|---|---|---|---|---|---|
| Monthly Commission | Company sales above $250,000 per month | Not disclosed | Not disclosed | Not disclosed | Monthly commission per agreement | N/A |
| Restricted Stock Grant | Service/performance per agreement | N/A | 138,114 shares (equals 1.75% of common stock) | Not disclosed | Grant fair value not disclosed | Subject to vesting as described in agreement; specific schedule not disclosed |
Equity Ownership & Alignment
| Item | Amount | Detail |
|---|---|---|
| Restricted Stock Granted | 138,114 shares | Equal to 1.75% of common stock; vesting terms not disclosed |
| Ownership as % Outstanding | 1.75% (from grant) | Total beneficial ownership breakdown not disclosed |
| Vested vs Unvested | Not disclosed | Employment agreement references vesting; schedule not provided |
| Options | None disclosed for Grawey | Executive option/RSU tables in proxy do not include Grawey |
| Shares Pledged as Collateral | None indicated in filings reviewed | Company states no arrangements including pledges known that could result in change in control as of record date |
| Insider Buying (PIPE) | Participated as Purchaser | Combined price $1.285 per share+warrant; warrant exercise price $1.16; 3‑year expiry |
Employment Terms
- At‑will employment; title: Chief Commercial Officer (CCO) .
- Compensation: $290,000 base salary, monthly commissions for sales above $250,000, and 138,114 shares of restricted stock equal to 1.75% of common stock; standard executive benefits .
- Severance and Change‑of‑Control: Not disclosed for Grawey in the filings reviewed .
- Non‑compete / Non‑solicit / Garden leave / Clawback / Tax gross‑ups: Not disclosed in available documents for Grawey .
Investment Implications
- Material equity alignment: A 138,114‑share restricted stock grant (~1.75% of common) creates meaningful long‑term alignment and vesting‑based retention incentives for the CCO .
- Pay for performance lever: A monthly commission tied to sales exceeding $250,000 directly links cash compensation to near‑term commercial execution, aligning incentives with revenue growth objectives .
- Insider capital commitment: Participation in the November 2025 PIPE at a $1.285 share+warrant price (warrant exercise $1.16, 3‑year term) signals willingness to invest alongside shareholders, a positive governance and alignment indicator .
- Retention risk assessment: Employment is at‑will with no disclosed severance or change‑of‑control economics for Grawey; retention therefore likely depends on equity vesting and performance results rather than guaranteed cash exit terms .